Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.99 USD
Change Today -0.03 / -0.21%
Volume 441.5K
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

nxstage medical inc (NXTM) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/27/15 - $19.63
52 Week Low
09/16/14 - $11.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NXSTAGE MEDICAL INC (NXTM)

Related News

No related news articles were found.

nxstage medical inc (NXTM) Related Businessweek News

No Related Businessweek News Found

nxstage medical inc (NXTM) Details

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product includes the System One, a portable hemodialysis system used for the treatment of acute and chronic kidney failure, and fluid overload. The company operates in three segments: System One, In-Center, and Services. The System One segment engages in the sale and rental of the NxStage System One and PureFlow SL dialysate preparation equipment, and sale of disposable products in the home and critical care markets. The home market focuses on the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting, and critical care market on the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers; and needles for apheresis. The Services segment provides dialysis services to patients at NxStage Kidney Care dialysis centers. NxStage Medical, Inc. markets its products through direct sales and distributors to hospitals and dialysis centers in the United States and internationally. The company, formerly known as QB Medical, Inc., was founded in 1998 and is headquartered in Lawrence, Massachusetts.

3,400 Employees
Last Reported Date: 02/26/15
Founded in 1998

nxstage medical inc (NXTM) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $496.9K
Total Annual Compensation: $338.6K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $305.6K
President of Nxstage Kidney Care
Total Annual Compensation: $306.4K
Senior Vice President of Quality Assurance, R...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

nxstage medical inc (NXTM) Key Developments

Nxstage Medical, Inc. Presents at William Blair & Company's 31st Annual Growth Stock Conference, Jun-15-2011

Nxstage Medical, Inc. Presents at William Blair & Company's 31st Annual Growth Stock Conference, Jun-15-2011 . Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States. Speakers: Jeffrey H. Burbank, Founder, Chief Executive Officer and Director.

NxStage Launches New Spanish-Language Resources for Hispanic Patients

NxStage Medical, Inc. announced the launch of new Spanish-language resources to improve accessibility of home hemodialysis (HHD) with the NxStage® System One for Spanish speaking dialysis patients. In addition to providing Spanish education and training materials, NxStage has expanded its full-service technical and customer support to include bilingual assistance.

Nxstage Medical, Inc. Announces Results from Dialysis Study

Nxstage Medical, Inc. has announced the results from a new study which found that patient survivability rates are higher with home hemodialysis, or HHD, than peritoneal dialysis, or PD. The Incident Cohort Study, the first of its size, was completed by the Australian and New Zealand Dialysis and transplantation Registry and shows that the five-year survival rate for HHD is at 85%, while the survival rate for PD patients is just 44%. It included 10,710 patients on incident peritoneal dialysis and 706 patients on incident home hemodialysis and found that the risk of death-censored technique failure for HHD was 66% lower than PD.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NXTM:US $13.99 USD -0.03

NXTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.21 USD -0.15
ICU Medical Inc $99.34 USD +1.24
Merit Medical Systems Inc $25.17 USD +0.32
Orthofix International NV $33.46 USD -0.17
RTI Surgical Inc $6.81 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation NXTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NXSTAGE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at